A thematic review of scientific and family interests in Canavan Disease: Where are the Developmentalists?

Journal of Intellectual Disability Research

Volumn 57, Issue 9, 2013, Pages 815-825

  Glicksman, S ^a,b   Borgen, C ^a   Blackstein, M ^a   Gordon, A ^a   Hanon, I ^a   Kusin, D ^a   Leibowitz, B ^a   Halle, J ^b  

^a YESHIVA UNIVERSITY   (United States)

^b Women's League Community Residences   (United States)

Author keywords

Canavan Disease; Carers; Intellectual disability; Parents

Indexed keywords

ACETIC ACID; CALCIUM ACETATE; TRIACETIN;

ARTICLE; BIOCHEMISTRY; CANAVAN DISEASE; GENETIC COUNSELING; HUMAN; NONHUMAN; PARENT;

CANAVAN DISEASE; CARERS; INTELLECTUAL DISABILITY; PARENTS;

ADULT; CANAVAN DISEASE; CAREGIVERS; CHILD; CHILD PSYCHOLOGY; HUMANS; INTELLECTUAL DISABILITY; INTERNET; SELF-HELP GROUPS;

EID: 84881662602     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2012.01576.x     Document Type: Article

References (70)

1. Al-Dirshibi O., Kurdi W., Imtiaz F., Imtiaz A., Asmahan M., Al-Sayad M. etal. (2009) Reliable prenatal diagnosis of Canavan Disease by measuring N-acetylaspartate in amniotic fluid using chromatography mass spectrometry. Prenatal Diagnosis 29, 477-80.
2. Arun P., Madhavo C., Moffett J., Hamilton K., Grunberg N., Ariyannur P. etal. (2010) Metabolic acetate therapy improves phenotype in tremor rat model of Canavan Disease. Journal of Inherited Metabolic Disease 33, 195-210.
3. Assadi M., Janson C., Wang D., Goldfarb O., Suri N., Bilaniuk L. etal. (2010) Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. European Journal of Paediatric Neurology 14, 354-9.
4. Baslow M. H. & Guilfoyle D. N. (2009) Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Neurochemistry Research 34, 1523-34.
5. Batzer F. & Ravitzky V. (2009) Preimplantation genetic diagnosis: ethical considerations. In: The Penn Center Guide to Bioethics (eds V. Ravitsky, A. Fiester & A. Caplan ), pp. 339-54. Springer Publishing Company, New York.
6. Birnbaum S., Levintow L., Kingsley R. & Greenstein J. (1952) Specificity of amino acid acylases. Journal of Biological Chemistry 194, 455-70.
7. Bitto E., Bingman C. A., Wesenberg G. E., McCoy J. G. & Phillips G. N. (2007) Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proceedings of the National Academy of Sciences of the United States of America. 104, 456-61.
8. Boulet S. L., Molinari N. A., Grosse S. D., Honein M. A. & Correa-Villaseñor A. (2008) Health care expenditures for infants and young children with Down syndrome in a privately insured population. Journal of Pediatrics 153, 241-6.
9. Caliebe A., Vater I., Plendl H., Gesk S., Siebert R., Cremer F. etal. (2010) A 439 kb-sized homozygous deletion in 17p13.3 leading to biallelic loss of the ASPA as cause of Canavan disease detected by SNP-array analysis. Molecular Genetic Metabolism 99, 184-5.
10. Canavan M. M. (1931) Schilder's encephalitis peraxialis diffusa. Report of a case in a child aged sixteen and one half months. Archives of Neurology and Psychiatry 25, 299-308.
11. Coughlin C. (2009) Prenatal choices: genetic counseling for variable genetic diseases. In: The Penn Center Guide to Bioethics (eds V. Ravitsky, A. Fiester & A. Caplan ), pp. 415-24. Springer Publishing Company, New York.
12. Della Marca G., Frusciante R., Dittoni S., Vollono C., Buccarella C., Iannaccone E. etal. (2009) Sleep disordered breathing in facioscapulohumeral muscular dystrophy. Journal of the Neurological Sciences 285, 54-8.
13. Di Pietro V., Gambacurta A., Amorini A., Finocchiaro A., D'Urso S., Ceccarelli L. etal. (2008) A new T677C mutation of the aspartoacylase gene encodes for a protein with no enzymatic activity. Clinical Biochemistry 41, 611-5.
14. Dotan K., Feldman B., Goldman B., Peri Y. & Peleg L. (2010) The single cell as a tool for genetic testing: credibility, precision, implication. Journal of Assisted Reproduction and Genetics 27, 335-41.
15. Fares F., Badarneh K., Abosaleh M., Harari-Shaham A., Diukman R. & David M. (2008) Carrier frequency of autosomal-recessive disorders in the Ashkenazi Jewish population: should the rationale for mutation choice for screening be reevaluated? Prenatal Diagnosis 28, 236-41.
16. Feigenbaum A., Moore R., Clarke J., Hewson S., Chitayat D., Ray P. etal. (2004) Canavan Disease: Carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. American Journal of Medical Genetics 124A, 142-47.
17. Finsterer J. (2009) Ataxias with autosomal, X-chromosomal or maternal inheritance. Canadian Journal of Neurological Sciences 36, 409-28.
18. Gibbons B. G., Williams K. E. & Riegel K. E. (2007) Reducing tube feeds and tongue thrust: Combining an oral-motor and behavioral approach to feeding. American Journal of Occupational Therapy 61, 384-91.
19. Globus J. & Strauss I. (1928) Progressive degenerative subcortical encephalopathy (Shilder's disease). Archives of Neurology and Psychiatry 20, 1190-228.
20. Godeiro-Junior C., Felicio A. C., Benites V., Chieia M. & Oliveira A. B. (2009) Late-onset hexosaminide: a deficiency mimicking primary lateral sclerosis. Arquivos de Neuro-psiquiatria 67, 105-6.
21. Hamaguchi H., Nihei K., Nakamoto N., Ezoe T., Naito H., Hara M. etal. (1993) A case of Canavan disease: the first biochemically proven case in a Japanese girl. Brain and Development 15, 367-71.
22. Harris K., Lin A., Bhattacharya P., Tran T., Wong W. & Ross B. (2006) Regulation of NAA-synthesis in the human brain in vivo: Canavan's disease, Alzheimer's disease and schizophrenia. Advances in Experimental Medicine and Biology 576, 263-73.
23. Hayase T., Shimzu J., Goto T., Nozaki Y., Mori M., Mariko Y. etal. (2010) Unilaterally and rapidly progressing white matter lesion with elevated cytokines in a patient with Tay-Sachs disease. Brain and Development 32, 244-7.
24. Hershfeld J., Pattabiraman N., Madhavarao C. & Namboodiri M. (2007) Mutational analysis of aspartoacylase: implications for Canavan Disease. Brain Research 1148, 1-14.
25. Hershfield J. R., Madhavarao C. N., Moffett J. R., Benjamins J. A., Garbern J. Y. & Namboodiri A. (2006) Aspartoacylase is a regulated nuclear-cytoplasmic enzyme. Journal of the Federation of American Societies for Experimental Biology 20, 2139-41.
26. Janson C. G., Assadi M., Francis J., Bilaniuk L., Shera D. & Leone P. (2005) Lithium citrate for Canavan Disease. Pediatric Neurology 33, 235-43.
27. Janson C. G., McPhee S., Francis J., Shera D., Assadi M., Freese A. etal. (2006) Natural history of Canavan Disease revealed by proton magnetic resonance spectroscopy (H-MRS) and diffusion-weighted MRI. Neuropediatrics 37, 209-21.
28. Kalman L., Wilson J., Buller A., Dixon L., Edelmann L., Geller L. etal. (2009) Development of genomic DNA reference materials for genetic testing of disorders common in people of Ashkenazi Jewish descent. Journal of Molecular Diagnostics 11, 530-6.
29. Kaya N., Imtiaz F., Colak D., Al-Sayed M., Al-Odaib A., Al-Zahrani F. etal. (2008) Genome-wide gene expression profiling and mutation analysis of Saudi patients with Canavan Disease. Genetics in Medicine 10, 675-84.
30. Kobayashi K., Tsujino S., Ezoe T., Hamaguchi H., Nihei K. & Sakuragawa N. (1998) Missense mutation (I143T) in a Japanese patient with Canavan disease. Human Mutation 11 (Suppl. 1), S308-S309.
31. Kolodziejczyk K., Hamilton N. B., Wade A., Káradóttir R. & Attwell D. (2009) The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes. Brain 132, 1496-508.
32. Kumar S., Mattan N. S. & de Vellis J. (2006) Canavan disease: a white matter disorder. Mental Retardation and Developmental Disabilities Research Reviews 12, 157-65.
33. Kumar S., Biancotti J., Matalon R. & de Vellis J. (2009) Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. Journal of Neuroscience Research 87, 3415-27.
34. Laberge L., Bégin P., Montplaisir J. & Mathieu J. (2004) Sleep complaints in patients with myotonic dystrophy. Journal of Sleep Research 13, 95-100.
35. Le Coq J., An H. J., Lebrilla C. & Viola R. E. (2006) Characterization of human aspartoacylase: the brain enzyme responsible for Canavan disease. Biochemistry 45, 5878-84.
36. Le Coq J., Pavlovksy A., Malik R., Sanishvili R., Xu C. & Viola R. (2008) Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue. Biochemistry 47, 3484-92.
37. McPhee S. W., Janson C. G., Li C., Samulski R. J., Camp A. S., Francis J. etal. (2006) Immune responses to AAV in a phase I study for Canavan disease. Journal of Gene Medicine 8, 577-88.
38. Madhavaroa C., Arun P., Anikster Y., Mog S., Staretz-Chacham O., Moffett J. etal. (2009) Glyceryl triacetate for Canavan Disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in a tremor rat model. Journal of Inherited Metabolic Disorders 32, 640-50.
39. Matalon R. & Michals-Matalon K. (2011) Canavan Disease. In: Gene Reviews [Internet] (eds R. A. Pagon, T. D. Bird, C. R. Dolan & K. Stephens ). University of Washington, Seattle, WA. Updated 11 August 2011.
40. Matalon R., Michals K., Sebesta D., Deanching M., Gashkoff P., Casanova J. etal. (1988) Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. American Journal of Medical Genetics 29, 463-71.
41. Matalon R., Kaul R. & Michals K. (1993) Canavan disease: biochemical and molecular studies. Journal of Inherited Metabolic Disease 16, 744-52.
42. Mersmann N., Tkachev D., Jelinek R., Roth P. T., Mbius W. etal. (2011) Aspartoacylase-LacZ knockin mice: an engineered model of Canavan Disease. PLoS ONE 6, e20336. doi:10.1371/journal.pone.0020336.
43. Moffet J., Ross B., Arun P., Madhavarao C. & Namboodiri A. (2007) N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Progress in Neurobiology 81, 89-131.
44. Moffett J. R. & Namboodiri A. M. A. (2006) Preface: a brief review of N-acetylaspartate. In: N-Acetylaspartate: A Unique Neuronal Molecule in the Central Nervous System (eds J. R. Moffett, S. B. Tieman, D. R. Weinberger, J. T. Coyle & A. M. A. Namboodiri ), pp. vii-xiii. Springer, New York, NY.
45. Moffett J., Arun P., Ariyannur P., Garbern J., Jacobowitz D. & Namboodiri A. (2011) Extensive aspartoacylase expression in the rat central nervous system. Glia 59, 1414-34.
46. Ozand P., Gascon G. & Dhalla M. (1990) Aspartoacylase deficiency and Canavan Disease in Saudi Arabia. American Journal of Medical Genetics 35, 266-8.
47. Pederzolli C. D., Rockenbach F. J., Zanin F. R., Henn N. T., Romagna E. C., Sgaravatti A. M. etal. (2009) Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats. Metabolic Brain Disease 24, 283-98.
48. Perea A., Meyer K., Paez J., Yelin K., Birchansky S., Jayakar P. etal. (1999) Canavan Disease in a patient of African origin. International Pediatrics 14, 111-3.
49. Pradhan S. & Goyal G. (2011) Teaching NeuroImages: honeycomb appearance of the brain in a patient with Canavan disease. Neurology 76, e68.
50. Rozenberg R., Kof F., Burin M. G., Miranda M. C., Vasquez C., Henrique-Souza A. M. M. etal. (2006) Diagnosis and molecular characterization of nonclassical forms of Tays-Sachs disease in Brazil. Journal of Molecular Neurology 21, 540-4.
51. Schriver I., Kulm M., Gardner P., Pergament E. & Fiddler M. (2007) Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population. Journal of Molecular Diagnostics 9, 228-36.
52. Segel R., Anikster Y., Zevin S., Steinberg A., Gahl W. A., Fisher D. etal. (2011) A safety trial of high dose glyceryl triacetate for Canavan disease. Molecular Genetics and Metabolism 103, 203-6.
53. Shapiro B. & Natowitcz M. (2009) Late-onset Tay-Sachs disease presenting as a childhood stutter. Journal of Neurology 80, 94-5.
54. Surendran S. (2009) Upregulation of N-acetylaspartic acid alters inflammation, transcription, and contractile associated protein levels in the stomach and smooth muscle contractility. Molecular Biology Reports 36, 201-6.
55. Surendran S. & Bhatnagar M. (2011) Upregulation of N-acetylaspartic acid induces oxidative stress to contribute in disease pathophysiology. International Journal of Neuroscience 121, 305-9.
56. Surendran S. & Rajasankar S. (2011) Aspartoacylase deficiency in the white matter of human immunodeficiency virus encephalitis: novel mechanism in axonal damage. Molecular Genetic Metabolism 103, 203-6.
57. Tacke U., Olbrich H., Sass J., Fekete A., Horvath J., Ziyeh S. etal. (2005) Possible genotype-phenotype correlations in children with mild clinical course of Canavan Disease. Neuropediatrics 36, 252-5.
58. Tieleman A. A., Knoop H., van de Logt A. E., Bleijenberg G., van Engelen B. G. & Overeem S. (2010) Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. Journal of Neurology, Neurosurgery and Psychiatry 81, 963-7.
59. Traka M., Wollmann R., Cerda S., Dugas J., Barres B. & Popko B. (2008) Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Journal of Neuroscience 28, 11537-49.
60. Tsuji D., Akeboshi H., Matsuoka K., Yasuoka H., Miyasaki E., Kasahara Y. etal. (2011) Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis. Annals of Neurology 69, 691-701.
61. Unalp A., Altiok E., Uran N., Ozturk A. & Yuksel S. (2008) Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease. Journal of Tropical Pediatrics 54, 208-10.
62. Velinov M., Zellers N., Styles J. & Wisneiwski K. (2008) Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease. Clinical Genetics 73, 288-9.
63. Wang J., Leone P., Wu G., Francis J., Li H., Jain M. etal. (2009) Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat. Neurochemical Research 34, 138-48.
64. Weinstein L. (2007) Selected genetic disorders affecting Ashkenazi Jewish families. Journal of Health Promotion and Maintenance 30, 50-62.
65. Yoshino H., Ariga T., Suzuki A., Yu R. & Miyatake T. (2008) Identification of gangliosides recognized by IgG anti-GaINAc antibodies in bovine spinal motor neurons and motor nerves. Brain Research 1227, 216-20.
66. Zelnik N. & Elpeleg O. N. (1994) Canavan disease: clinical-genetic correlation. Developmental Medicine and Child Neurology 36, 845.
67. Zelnik N., Luder A. S., Elpeleg O. N., Gross-Tsur V., Amir N., Hemli J. A. etal. (1993) Protracted clinical course for patients with Canavan disease. Developmental Medicine and Child Neurology 35, 355-9.
68. Zeng B. J., Pastores G. M., Leone P., Raghavan S., Wang Z. H., Ribeiro L. A. etal. (2006a) Mutation analysis of the aspartoacylase gene in non-Jewish patients with Canavan Disease. Advances in Experimental Medicine and Biology 576, 165-73.
69. Zeng B. J., Wang Z. H., Torres P. A., Pastores G. M., Leone P., Raghavan S. S. etal. (2006b) Rapid detection of three large novel deletions of the aspartoacylase gene in non-Jewish patients with Canavan disease. Molecular Genetics and Metabolism 89, 156-63.
70. Zhang H., Liu X. & Gu X. (2010) Two novel missense mutations in the aspartocacylase gene in a Chinese patient with congenital Canavan Disease. Brain and Development 32, 879-82.